Shenzhen Capital Group Co-Leads $62M Round In Chinese Biopharmaceutical Firm Zelgen

Login to View

Shenzhen Capital Group Co., Ltd, Minsheng Life Insurance and Share Capital have led a RMB400 million (US$62 million) series B round in Suzhou Zelgen Biosciences Co., Ltd., a Chinese biopharmaceutical company.

Continue reading with a China Money Network subscription


Join Now

Already have an account or paid subscription? Log in


RELATED NEWS



LEAVE A REPLY

Please enter your comment!
Please enter your name here